A Hypoxia-Targeted Boron Neutron Capture Therapy Agent for the Treatment of Glioma

Pharmaceutical Research

Volumn 33, Issue 10, 2016, Pages 2530-2539

  Luderer, Micah John ^a   Muz, Barbara ^a   de la Puente, Pilar ^a   Chavalmane, Sanmathi ^b   Kapoor, Vaishali ^a   Marcelo, Raymundo ^a   Biswas, Pratim ^b   Thotala, Dinesh ^a   Rogers, Buck ^a   Azab, Abdel Kareem ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

Author keywords

BNCT; boron neutron capture therapy; glioma; hypoxia; tumor targeting

Indexed keywords

2 NITROIMIDAZOLE DERIVATIVE; 4 BORONOPHENYLALANINE; BORON DERIVATIVE; NITROIMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; BORON NEUTRON CAPTURE THERAPY; CANCER RADIOTHERAPY; CELL TRANSPORT; CELL VIABILITY ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG RETENTION; DRUG SYNTHESIS; FEMALE; GLIOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; HYPOXIC CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; ANIMAL; BRAIN TUMOR; CELL HYPOXIA; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; NUDE MOUSE; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; BRAIN NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GLIOMA; MICE; MICE, NUDE; NITROIMIDAZOLES; TREATMENT OUTCOME;

EID: 84978069212     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-016-1977-2     Document Type: Article

References (39)

1. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2(9):494–503. quiz 1 p following 16.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-years analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.
4. Cv R, Wilhelm A, Sauerwein WG, Av L. Boron neutron capture therapy for glioblastoma multiforme. Pharm World Sci. 2005;27(2):92–5.
5. Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma—are we there yet? Neuro-Oncology. 2012.
6. Azab AK, Abu Ali H, Srebnik M. Chapter 5 Boron neutron capture therapy. In: Hijazi Abu Ali VMD, Morris S, editors. Studies in Inorganic Chemistry: Elsevier; 2006. p. 337–66.
7. Luderer M, de la Puente P, Azab A. Advancements in tumor targeting strategies for boron neutron Capture Therapy. Pharm Res. 2015:1–13.
8. Barth RF, Coderre JA, Vicente MGH, Blue TE. Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res. 2005;11(11):3987–4002.
9. Chandra S, Barth RF, Haider SA, Yang W, Huo T, Shaikh AL, et al. Biodistribution and subcellular localization of an unnatural boron-containing amino acid (cis-ABCPC) by imaging secondary ion mass spectrometry for neutron capture therapy of melanomas and gliomas. PLoS ONE. 2013;8(9):e75377.
10. Pellettieri L, H-Stenstam B, Rezaei A, Giusti V, Sköld K. An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme. Acta Neurol Scand. 2008;117(3):191–7.
11. Brat DJ, Mapstone TB. Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann Intern Med. 2003;138(8):659–68.
12. Snajdr I, Janousek Z, Takagaki M, Cisarova I, Hosmane NS, Kotora M. Alpha (alpha-) and beta beta-carboranyl-C-deoxyribosides: syntheses, structures and biological evaluation. Eur J Med Chem. 2014;83:389–97.
13. Muz B, de la Puente P, Azab F, Luderer M, Azab AK. The role of hypoxia and exploitation of the hypoxic environment in hematologic malignancies. Mol Cancer Res. 2014;12(10):1347–54.
14. Oliver L, Olivier C, Marhuenda FB, Campone M, Vallette FM. Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy. Curr Mol Pharmacol. 2009;2(3):263–84.
15. Fu Y, Zheng S, Zheng Y, Huang R, An N, Liang A, et al. Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1alpha and beta-catenin signaling: possible impact on glioma cell metastasis and chemo-resistance. Int J Biochem Cell Biol. 2012;44(5):770–5.
16. Greenfield JP, Cobb WS, Lyden D. Resisting arrest: a switch from angiogenesis to vasculogenesis in recurrent malignant gliomas. J Clin Invest. 2010;120(3):663–7.
17. Haar CP, Hebbar P, Wallace GC, Das A, Vandergrift 3rd WA, Smith JA, et al. Drug resistance in glioblastoma: a mini review. Neurochem Res. 2012;37(6):1192–200.
18. Amberger-Murphy V. Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets. 2009;9(3):381–90.
19. Rycaj K, Tang DG. Cancer stem cells and radioresistance. Int J Radiat Biol. 2014;90(8):615–21.
20. Bell C, Dowson N, Fay M, Thomas P, Puttick S, Gal Y, et al. Hypoxia imaging in gliomas with F-fluoromisonidazole PET: toward clinical translation. Semin Nucl Med. 2015;45(2):136–50.
21. Parker NR, Khong P, Parkinson JF, Howell VM, Wheeler HR. Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol. 2015;5:55.
22. Bernsen HJ, Rijken PF, Peters H, Raleigh JA, Jeuken JW, Wesseling P, et al. Hypoxia in a human intracerebral glioma model. J Neurosurg. 2000;93(3):449–54.
23. Olive PL, Durand RE, Raleigh JA, Luo C, Aquino-Parsons C. Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia. Br J Cancer. 2000;83(11):1525–31.
24. de la Puente P, Azab F, Muz B, Luderer M, Arbiser J, Azab AK. Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma. Leuk Lymphoma. 2015:1–10.
25. William T. Golde PG, Luis L. Rodriguez. A rapid, simple, and humane method for submandibular bleeding of mice using a lancet. Lab Animal. 2005;34(9):4.
26. Liberman SJ, Dagrosa A, Jimenez Rebagliati RA, Bonomi MR, Roth BM, Turjanski L, et al. Biodistribution studies of boronophenylalanine-fructose in melanoma and brain tumor patients in Argentina. Appl Radiat Isot. 2004;61(5):1095–100.
27. Aihara T, Hiratsuka J, Morita N, Uno M, Sakurai Y, Maruhashi A, et al. First clinical case of boron neutron capture therapy for head and neck malignancies using 18 F-BPA PET. Head Neck. 2006;28(9):850–5.
28. Wittig A, Malago M, Collette L, Huiskamp R, Buhrmann S, Nievaart V, et al. Uptake of two 10B-compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC trial 11001). Int J Cancer. 2008;122(5):1164–71.
29. Neumann M, Bergmann M, Gabel D. Cell type selective accumulation of mercaptoundecahydro- closo-dodecaborate (BSH) in glioblastoma multiforme. Acta Neurochir. 2003;145(11):971–5.
30. Wittig A, Collette L, Appelman K, Buhrmann S, Jackel MC, Jockel KH, et al. EORTC trial 11001: distribution of two 10B-compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial. J Cell Mol Med. 2009;13(8B):1653–65.
31. Varia MA, Calkins-Adams DP, Rinker LH, Kennedy AS, Novotny DB, Fowler WC, et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol. 1998;71(2):270–7.
32. Varghese AJ, Gulyas S, Mohindra JK. Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo. Cancer Res. 1976;36(10):3761–5.
33. Genady AR, Ioppolo JA, Azaam MM, El-Zaria ME. New functionalized mercaptoundecahydrododecaborate derivatives for potential application in boron neutron capture therapy: synthesis, characterization and dynamic visualization in cells. Eur J Med Chem. 2015;93:574–83.
34. Pisarev MA, Dagrosa MA, Juvenal GJ. Boron neutron capture therapy in cancer: past, present and future. Arq Bras Endocrinol Metabol. 2007;51(5):852–6.
35. Barth RF, Vicente MG, Harling OK, Kiger 3rd WS, Riley KJ, Binns PJ, et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol. 2012;7(146):7–146.
36. Soloway AH, Tjarks W, Barnum BA, Rong F-G, Barth RF, Codogni IM, et al. The chemistry of neutron capture therapy. Chem Rev. 1998;98(4):1515–62.
37. Hawthorne MF, Lee M. A critical assessment of boron target compounds for boron neutron capture therapy. J Neuro-Oncol. 2003;62(1–2):33–45.
38. Hosmane NS. Boron and gadolinium neutron capture therapy for cancer treatment. Singapore, SGP: World Scientific Publishing Co.; 2012.
39. Hosmane NS. Boron science: new technologies and applications. Boca Raton, FL: CRC Press; 2012.